Malvern, Pa.-based Ceptaris Therapeutics Inc. received FDA marketing approval for its single asset, Valchlor (mechlorethamine) gel, for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma, in patients who have received prior skin-directed therapy.